Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

被引：0
|
作者：
Sabrina Wiebe
David Schnell
Raimund Külzer
Dietmar Gansser
Anne Weber
Gudrun Wallenstein
Atef Halabi
Anja Conrad
Sven Wind
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG,Translational Medicine and Clinical Pharmacology
[2] Datamap GmbH,undefined
[3] Clinical Research Services (CRS) Kiel GmbH,undefined
来源：
European Journal of Drug Metabolism and Pharmacokinetics | 2017年 / 42卷
关键词：
Renal Impairment; Epidermal Growth Factor Receptor Mutation; Plasma Protein Binding; Severe Renal Impairment; Advanced Solid Tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：461 / 469
页数：8
相关论文
共 50 条
  • [1] Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
    Wiebe, Sabrina
    Schnell, David
    Kuelzer, Raimund
    Gansser, Dietmar
    Weber, Anne
    Wallenstein, Gudrun
    Halabi, Atef
    Conrad, Anja
    Wind, Sven
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (03) : 461 - 469
  • [2] Effect of renal impairment on the pharmacokinetics of prucalopride: a single-dose open-label Phase I study
    Smith, William B.
    Mannaert, Erik
    Verhaeghe, Tom
    Kerstens, Rene
    Vandeplassche, Lieve
    Van de Velde, Vera
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2012, 6 : 407 - 415
  • [3] PHARMACOKINETICS OF SETMELANOTIDE IN INDIVIDUALS WITH RENAL IMPAIRMENT: RESULTS FROM A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY
    Zacchia, Miriam
    Navarria, Andrea
    Baughman, Sharon
    Roux, Willem
    Malhotra, Sonali
    Yuan, Guojun
    Cetiner, Metin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I1133 - I1133
  • [4] Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study
    Kobalava, Zhanna
    Villevalde, Svetlana
    Kotovskaya, Yulia
    Hinrichsen, Holger
    Petersen-Sylla, Marc
    Zaehringer, Andreas
    Pang, Yinuo
    Rajman, Iris
    Canadi, Jasna
    Dahlke, Marion
    Lloyd, Peter
    Halabi, Atef
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (06) : 937 - 945
  • [5] Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study
    David, Olivier J.
    Pryce, Maxwell
    Meiser, Karin
    Picard, Franck
    Emotte, Corinne
    Kobalava, Zhanna
    Moiseev, Valentin
    Schmouder, Robert
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (10) : 847 - 854
  • [6] A Phase 1, Open-Label, Single-Dose Study to Evaluate Pharmacokinetics of MEDI0382 in Patients with Renal Impairment
    Klein, Gernot K.
    Petrone, Marcella
    Yang, Ye
    Hoang, Thuong
    Dicostanza, Sheila
    Hansen, Lars
    Flor, Armando
    DIABETES, 2019, 68
  • [7] Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
    Kasichayanula, Sreeneeranj
    Liu, Xiaoni
    Zhang, Weijiang
    Pfister, Marc
    LaCreta, Frank P.
    Boulton, David W.
    CLINICAL THERAPEUTICS, 2011, 33 (11) : 1798 - 1808
  • [8] Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study
    Kim, Seokuee
    Lee, Jongtae
    Shin, Donghoon
    Lim, Kyoung Soo
    Kim, Yon Su
    Jang, In-Jin
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1723 - 1731
  • [9] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Yalcin Solak
    Seyyid Bilal Acikgoz
    Mehmet Yildirim
    Clinical Drug Investigation, 2015, 35 : 149 - 149
  • [10] Single-Dose, Open-Label Study of the Differences in Pharmacokinetics of Colchicine in Subjects with Renal Impairment, Including End-Stage Renal Disease
    Solak, Yalcin
    Acikgoz, Seyyid Bilal
    Yildirim, Mehmet
    CLINICAL DRUG INVESTIGATION, 2015, 35 (02) : 149 - 149
12345